Search for a trial

A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination
With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung
Cancer

This study has been transitioned to CTIS with ID 2024-511021-58-00 check the CTIS register for the current data. Primary Objective:- Number of participants with dose limiting toxicity - Number of participants with treatment-related adverse events -…

Utrecht Breathing Regulation Effectiveness for Abdominal and THoracic External-beam Radiotherapy (U-BREATHER)

To assess the feasibility of participants positioned in an MRI scanner to regulate their breathing based on biofeedback

A Prospective Investigation to Assess the Diagnostic Yield of using a Robotic Navigational Bronchoscopy System with Adjunct Real-time Imaging

The primary objective of this Clinical Investigation is to evaluate the diagnostic yield using the Ion Endoluminal System when used with adjunctive 3D imaging modalities for the biopsy of peripheral pulmonary nodules (PPNs). In a first phase, the…

A Phase IIB, Open Label, Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET-CT in Subjects with Selected Advanced or Metastatic Malignancies including Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers, Scheduled to Receive Standard-of-Care Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy

Primary objective: evaluate the performance of zirconium Zr 89 crefmirlimab berdoxam PET-CT for predicting patient response to immunotherapy. Secondary objectives: - evaluate the performance of zirconium Zr 89 crefmirlimab berdoxam PET-CT for…

A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor

This study has been transitioned to CTIS with ID 2024-513770-22-00 check the CTIS register for the current data. Primary objective:• Evaluate the anti-tumor activity of GEN1046 as monotherapy and in combination with pembrolizumab in subjects with…

NVALT28/ PRL01: Durvalumab and low-dose Prophylactic Cranial Irradiation (PCI) versus durvalumab and observation in radically treated patients with stage III non-small cell lung cancer: A phase III randomized study

To evaluate whether the addition of PCI to durvalumab after concurrent chemo-radiotherapy for stage III NSCLC reduces the cumulative incidence of brain metasta-ses

A Phase 1/2, open-label, multicenter, dose escalation and dose expansion study of SAR442720 in combination with other agents in participants with advanced malignancies

The primary goal of Part 3 of this study is to evaluate the safety, recommended phase 2 dose (RP2D), antitumor effect and PK of SAR442720 in combination with KRAS G12C inhibitor adagrasib, in participants with NSCLC with KRAS G12C mutationsPart-3a…

A PHASE II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB, WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY, IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON-SMALL CELL LUNG CANCER.

This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone (Atezo + Tira) or in combination with platinum-based chemotherapy (Atezo + Tira + Chemo) as neoadjuvant treatment for patients with previously…

Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer With or Without Actionable Genomic Alterations

This study has been transitioned to CTIS with ID 2023-509865-19-00 check the CTIS register for the current data. To compare the efficacy of DS-1062a with that of docetaxel, as measured by PFS and OS, for subjects with NSCLC with or without…

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

This study has been transitioned to CTIS with ID 2022-502977-41-00 check the CTIS register for the current data. Primary ObjectiveTo assess the efficacy of furmonertinib compared to platinum-based chemotherapy using progression-free survival (PFS)…

Long term effect of definitive chemoradiotherapy on respiratory function tests in patients with locally advanced (non)-small cell lung carcinoma

The aim of the study is to evaluate the change of lung function at least one year after definitive chemoradiation (concurrent or sequential) or radiotherapy alone in patients with locally advanced (non) small cell lung carcinoma to assess late…

KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression >= 1% and an STK11 co-mutation.

This study has been transitioned to CTIS with ID 2024-511708-18-00 check the CTIS register for the current data. the Sponsor aims to investigate if JDQ443 will stop abnormal cell growth related to the marker KRAS G12C mutation in patients with NSCLC…

Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer

This study has been transitioned to CTIS with ID 2023-505514-15-00 check the CTIS register for the current data. Primary Objective:- To investigate whether adding TRT to durvalumab plus chemotherapy improves 1-year survival. Secondary Objectives:-…

INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701

Primary Objective: • To determine whether there is a correlation between intratumoral DM4 exposure and response to treatment, defined as maximal tumor size deviation of the biopsied lesion according to Response Evaluation Criteria In Solid Tumors (…

Adoptive TIL therapy in combination with chemoimmunotherapy in advanced NSCLC patients

This study has been transitioned to CTIS with ID 2024-517939-53-00 check the CTIS register for the current data. Primary: To evaluate the safety and toxicity of TIL therapy in patients with metastatic NSCLC preceded by chemotherapy with or without…

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

This study has been transitioned to CTIS with ID 2023-509137-39-00 check the CTIS register for the current data. Primary/dualco-primary. To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (…

Implementation of up-front ctDNA analysis into lung cancer care and development of liquid biopsy-based decision support models - the Lungmarker2 study

This study implements up-front ctDNA analysis ('plasma first approach') into routine diagnostic work-up of all advanced stage LC patients in the Southeast of the Netherlands (the participating hospitals in the OncoZON region). Thereby,…

A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations

This study has been transitioned to CTIS with ID 2023-509825-38-00 check the CTIS register for the current data. To compare the effect of ZIM and DOM in combination with chemotherapy relative to PEMBRO in combination with chemotherapy (Group A…

Upfront resection of locally-advanced or cavitating NSCLC followed by chemoradiotherapy (and adjuvant systemic treatment); Phase 1 multicenter study to assess treatment feasibility and safety

The primary aim of the UPLAN-I trial is to evaluate feasibility and safety of upfront resection of large volume or cavitating tumors in the lung (including a hilar and/or mediastinal lymph node dissection if deemed possible by the treating surgeon…

RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WITH AND WITHOUT CENTRAL NERVOUS SYSTEM METASTASES

This study has been transitioned to CTIS with ID 2023-507494-18-00 check the CTIS register for the current data. This study will evaluate the efficacy and safety of entrectinib compared with crizotinib in patients who have NSCLC harboring ROS1 gene…